Method and composition for treatment of skeletal dysplasias

Abstract

The present invention relates to a method for the treatment of skeletal dysplasia by administering to a patient a composition comprising a therapeutically effective amount of at least one C-type natriuretic peptide (CNP).

1 . A method for the treatment of skeletal dysplasia comprising the step of administering to a patient a composition comprising a therapeutically effective amount of at least one natriuretic peptide. 
     
     
         2 . The method according to  claim 1 , wherein the at least one natriuretic peptide is a C-type natriuretic peptide (CNP). 
     
     
         3 . The method according to  claim 2 , wherein the C-type natriuretic peptide is human CNP as set forth in SEQ ID NO: 1. 
     
     
         4 . The method according to  claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier or excipient. 
     
     
         5 . The method according to  claim 4 , wherein the pharmaceutically acceptable carrier or excipient is selected from polymers, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, and gelatin. 
     
     
         6 . The method according to  claim 4 , wherein the pharmaceutically acceptable carrier or excipient is polyethylene glycol. 
     
     
         7 . The method according to  claim 1 , wherein the composition comprises natriuretic peptide secreting cells. 
     
     
         8 . The method according to  claim 7 , wherein the natriuretic peptide secreting cells are transplanted or implanted to the site of a lesion. 
     
     
         9 . The method according to  claim 7 , wherein the natriuretic peptide secreting cells are encapsulated within an inert matrix. 
     
     
         10 . The method according to  claim 9 , wherein the natriuretic peptide secreting cells are encapsulated within an alginate-polylysine-alginate complex. 
     
     
         11 . The method according to  claim 1 , wherein the composition is administered in liquid or suspension form. 
     
     
         12 . The method according to  claim 1 , wherein the composition is administered in an injectable, implantable or transplantable form. 
     
     
         13 . The method according to  claim 1 , wherein the skeletal dysplasia is achondroplasia. 
     
     
         14 . The method according to  claim 1 , wherein the treatment comprises abnormal bone growth. 
     
     
         15 . The method according to  claim 14 , wherein bone growth comprises bone elongation.